Status:
COMPLETED
Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis
Lead Sponsor:
Mologic Ltd
Collaborating Sponsors:
Heart of England NHS Foundation Trust
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis
Detailed Description
People with cystic fibrosis (CF) are prone to chest infections (pulmonary exacerbations) and suffer premature death due to respiratory failure. Patients that experience more frequent pulmonary exacerb...
Eligibility Criteria
Inclusion
- Confirmed CF diagnosis
- Aged \>18 years of age
- Patients able and willing to give informed consent
- Requirement for at least one course of intravenous antibiotics for a pulmonary exacerbation within the previous 3 months.
Exclusion
- Patients not able or not willing to give informed consent
- Patients who are currently participating in another clinical trial (excluding observational studies)
- Pneumothorax or lung surgery within the previous 3 months, eye surgery (e.g. cataract operation) in the previous 4 weeks, or any other factor that prevents safe measurement of spirometry.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2019
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04297709
Start Date
February 1 2018
End Date
July 31 2019
Last Update
March 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Heartlands Hospital
Birmingham, United Kingdom, B9 5SS